Stay up-to-date on new clinical findings in Oncoderm.
Oncoderm Articles
Oncoderm Articles
Non-Invasive Treatment of Basal Cell Carcinoma: Photodynamic Therapy Following Curettage
Background: To investigate the effectiveness, safety, patient satisfaction, and cosmetic outcome of Methyl Aminolevulinate-Photodynamic Therapy (MAL-PDT) following curettage in order to make recommendations for its use in dermatology practices.
Anti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review
Background: Monoclonal antibodies encompass an increasingly important treatment for a variety of dermatologic conditions including hidradenitis suppurativa (HS). The high failure rate and cost of anti-tumor necrosis alpha (TNF-α) agents and emergence of biologic treatments critically warrant treatment strategies that identify treatment failures early and optimize therapy. This review’s primary objective is to understand the current literature on biologic therapeutic drug monitoring (TDM) used in chronic inflammatory diseases and apply this knowledge to future dermatologic studies and treatment.
Utility of Gene Expression Profiling in Skin Cancer: A Comprehensive Review
Understanding the metastatic potential of a skin cancer is essential to effective management. Gene expression profiling (GEP) is an innovative technology that has allowed for a better understanding of tumor biology in various skin cancers. Current methods focus on identifying and quantifying ribonucleic acid (RNA) transcripts in tissue samples. Using reverse transcriptase-polymerase chain reaction, specific RNA transcripts are reverted into deoxyribonucleic acid (DNA) for quantification…
Assessing the Efficacy of Imiquimod Use in Patients With Persistent Locally Advanced Melanoma In Situ
Background: The standard of care when treating melanoma in situ (MMIS) is an excision with at least 5 mm surgical margins.1 Some studies have suggested up to 9 mm margins to maximize local recurrence-free survival.2 This retrospective review aims to assess the efficacy of imiquimod as a topical treatment for persistently positive MMIS at the margins of prior excisions or where surgery is not an option.
Diversifying the Mohs Workforce: Understanding Barriers of Applicants to Mohs Micrographic Surgery Fellowship
Background: The population of the United States is becoming increasingly diverse, yet dermatology, especially Mohs micrographic surgery (MMS), lags behind.
Read More Articles
Oncoderm Editorials
Eruptive Squamous Cell Carcinomas Following Treatment With Fludarabine and Discussion of Treatment
Shah M, Wald J, Hanke CW. Eruptive Squamous cell carcinomas following treatment with fludarabine and discussion of treatment. J Drugs Dermatol. 2023;22(5):509-510.
Dilute Intralesional 5-Fluorouracil for the Treatment of Squamous Cell Carcinomas and Keratoacanthomas: A Case Series
Background: Intralesional 5-fluorouracil (5-FU) is a promising, yet sparsely studied alternative to surgical treatment for nonmelanoma skin cancer (NMSC).1 Previous studies of intralesional 5-FU have reported concentrations ranging from 30 to 50 mg/mL. To the best of our knowledge, this case series represents the first reported use of intralesional 5-FU 10.0 mg/mL and 16.7 mg/mL for NMSC.
Read More Editorials
Advertisement
Podcasts
Saving Skin, Hair & Nails with Supportive Oncodermatology: A Call to Action for All Those Involved
While the old adage, “more oncology treatments, more skin problems,” becomes more like dogma every day with each new life saving therapy, fear not my friends, help is out there. Joining JDD podcast host Dr. Adam Friedman again, the man, the myth, the supportive oncodermatology legend, Dr. Mario Lacouture shares the latest guidance on managing these hair, skin and nail toxicities that are often considered by the patient even worse then the cancer these drugs treat. Get your support on – your patients will thank you.
This podcast series is supported by La Roche-Posay.
Heal the Burn: Radical Updates for the Management of Radiation Dermatitis
All of those wonderful life saving toys the radiation oncologists get to play with come at a cost to an important bystander – the skin. Radiation dermatitis can be exquisitely disabling, and interfere with a patient’s treatment course. Enter Dr. Beth McLellan, Chief of Dermatology at the Albert Einstein College of Medicine who is soothing XRT burns and taking names. Tune in to part two of this three part supportive oncodermatology series as host Dr. Adam Friedman discusses how to best coordinate care with our oncology friends and manage and hopefully prevent this expected adverse event with this one rad derm. Phasers set to educate.
This podcast series is supported by La Roche-Posay.
Supplements
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm
An increasing number of patients survive or are living with cancer. Anticancer treatments frequently have cutaneous adverse events (cAEs) that may severely impact patients’ quality of life and interrupt anticancer treatment. The US Cutaneous Oncodermatology Management (USCOM) project aims to improve cancer patients’ and survivors’ quality of life by offering tools for preventing and managing cAEs.
Read More
